Tumor Cell Selectivity
Tumor Cell Selectivity is a biological targeting metric that distinguishes the preferential uptake or binding of Auger electron-emitting radiopharmaceuticals by tumor cells relative to surrounding healthy tissues, based on molecular, metabolic, or receptor-specific differences.
651
Publications
38.5K
Citations
4.4K
Authors
1.1K
Institutions
Publications per year
2017–2026
218
Parents
651
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Pamela A. Trail, David Willner, Shirley J. Lasch et al. · Science · 1993 · 554 citations
Medicine, Oncology, Pharmacology +16
Fabio Sonvico, Stéphane Mornet, Sébastien Vasseur et al. · Bioconjugate Chemistry · 2005 · 480 citations
The proteasome inhibitor PS-341 in cancer therapy.
B A Teicher, G Ara, Roy S. Herbst et al. · PubMed · 1999 · 473 citations
Medicine, Oncology, Pharmacology +13
1–5 of 651
4.4K
9
h-index
5
h-index
5
h-index
5
h-index
5
h-index
1–5 of 4.4K
1.1K
The University of Texas MD Anderson Cancer Center
Houston, United States
15 h-index
48 publications
5.2K citations
National Institutes of Health
Bethesda, United States
13 h-index
46 publications
5.5K citations
Harvard University
Cambridge, United States
12 h-index
65 publications
5.6K citations

Centre National de la Recherche Scientifique
Paris, France
12 h-index
59 publications
7.1K citations
Heidelberg University
Heidelberg, Germany
11 h-index
21 publications
968 citations
Inserm
Paris, France
10 h-index
49 publications
2.1K citations

Chinese Academy of Sciences
Beijing, China
10 h-index
45 publications
1.9K citations

Sun Yat-sen University
Guangzhou, China
10 h-index
35 publications
1.2K citations
1–8 of 1.1K
Repository · 61 publications · 5.5K citations
39
h-index
26 publications · 2.9K citations
26
h-index
21 publications · 1.5K citations
20
h-index
MCT · 17 publications · 1.4K citations
16
h-index
15 publications · 1K citations
15
h-index
1–5